Platelet P2Y12 receptor inhibition: An update on clinical drug development

American Journal of Cardiovascular Drugs

Volumn 10, Issue 4, 2010, Pages 217-226

  Vivas, David ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cangrelor, therapeutic use; Clopidogrel, therapeutic use; Elinogrel, therapeutic use; Platelet disorders, treatment; Prasugrel, therapeutic use; Purinoceptor P2Y12 antagonists, therapeutic use; Research and development; Ticagrelor, therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CLOPIDOGREL; ELINOGREL; METOPROLOL; PRASUGREL; PRT 060128; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; APLASTIC ANEMIA; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG DESIGN; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 77954985845     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11537670-000000000-00000     Document Type: Review

References (70)

1. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24): 2482-2494
2. Angiolillo DJ,UenoM, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74 (4): 597-607
3. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22): 2373-2383
4. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
5. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18 (7): 1587-1593
6. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101 (24): 2823-2828
7. Yusuf S, Zhao F,Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7): 494-502
8. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-2420
9. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-533
10. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy formyocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12): 1179-1189
11. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497): 1607-1621
12. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273 (4): 2024-2029
13. Angiolillo DJ. ADP receptor antagonism: whats in the pipeline? Am J Cardiovasc Drugs 2007; 7 (6): 423-432
14. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation: II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273 (4): 2030-2034
15. Daniel JL, Dangelmaier C, Jin J, et al. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999; 82 (4): 1322-1326
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49 (14): 1505-1516
17. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1 (8649): 1215-1220 (Pubitemid 19140324)
18. Nagakawa Y, Akedo Y, Orimo H, et al. Effect of the combination of antiplatelet agents in man: combination of aspirin, trapidil, ticlopidine and dipyridamole. Thromb Res 1990; 60 (6): 469-475
19. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334 (17): 1084-1089
20. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic- drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339 (23): 1665-1671
21. Bertrand ME, LegrandV, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus Aspirin and Ticlopidine (fantastic) study. Circulation 1998; 98 (16): 1597-1603
22. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998; 98 (20): 2126-2132
23. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102 (6): 624-629
24. Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 63 (1): 60-76
25. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102 (1): 7-14
26. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120 (22): 2271-2306
27. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116(7): e148-304
28. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374-1382
29. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl JMed 2006; 354 (16): 1706-1717
30. Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dualantiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28 (18): 2200-2207
31. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005; 111 (9): 1153-1159
32. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53 (10): 849-856
33. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25 (21): 1903-1910
34. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48 (5): 931-938
35. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112 (19): 2946-2950
36. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-STsegment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48 (7): 1339-1345
37. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111 (16): 2099-2106
38. Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100 (8): 1199-1206
39. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28 (15): 1814-1819
40. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115 (6): 708-716
41. Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions: results of a randomized study. Thromb Haemost 2008; 99 (1): 161-168
42. Angiolillo DJ, Costa MA, Shoemaker SB, et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008; 101 (4): 440-445
43. Lemesle G, Delhaye C, Sudre A, et al. Impact of high loading andmaintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am Heart J 2009; 157 (2): 375-382
44. Nunez-Gil IJ, Fernandez-Ortiz A, Perez-Isla L, et al. Clinical and prognostic comparison between left ventricular transient dyskinesia and a first non-STsegment elevation acute coronary syndrome. Coron Artery Dis 2008; 19 (7): 449-453
45. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51 (14): 1404-1411
46. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103 (1): 5-10
47. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157 (5): 818-824, 824 e811
48. Angiolillo DJ, Suryadevara S, Capranzano P, et al. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 2008; 9 (16): 2893-2900
49. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156 (2 Suppl.): S10-5
50. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116 (25): 2923-2932
51. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes.NEngl J Med 2007; 357 (20): 2001-2015 (Pubitemid 350106708)
52. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371 (9621): 1353-1363
53. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118 (16): 1626-1636
54. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373 (9665): 723-731
55. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J AmColl Cardiol 2008; 51 (21): 2028-2033
56. Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010; 8 (2): 151-158
57. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008; 156 (2 Suppl.): S23-8
58. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27 (9): 1038-1047
59. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140 a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50 (19): 1852-1856
60. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045-1057
61. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375 (9711): 283-293
62. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009; 7 (10): 1195-1201
63. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.ThrombHaemost 2001; 85 (3): 401-407
64. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the plateletADP receptor antagonists clopidogrel andAR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13 (7): 407-413
65. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361 (24): 2330-2341
66. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361 (24): 2318-2329
67. Gretler D, Conley P, Andre P, et al. First in human experience with PRT060128, a new direct-acting, reversible, P2Y12 inhibitor for IV and oral use [abstract]. J Am Coll Cardiol 2007; (49): 326A
68. Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 2009; 8 (1): 43-53
69. Gurbel P, Conley P, Andre P, et al. Oral dosing of PRT060128, a novel directacting, reversible P2Y12 antagonist overcomes high platelet reactivity in patients non-responsive to clopidogrel therapy [abstract]. Circulation 2008; (118): S-972
70. Berger JS, Roe MT, Gibson CM, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009; 158 (6): 998-1004 e1001